{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:13:20Z","timestamp":1761894800049,"version":"3.35.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1007\/s11912-008-0062-3","type":"journal-article","created":{"date-parts":[[2008,10,15]],"date-time":"2008-10-15T07:32:50Z","timestamp":1224055970000},"page":"404-411","source":"Crossref","is-referenced-by-count":10,"title":["Novel therapies in peripheral T-cell lymphomas"],"prefix":"10.1007","volume":"10","author":[{"given":"Hilary M.","family":"O\u2019Leary","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry J.","family":"Savage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,16]]},"reference":[{"key":"62_CR1","volume-title":"World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues","author":"E.S. Jaffe","year":"2001","unstructured":"Jaffe ES, Harris NL, Stein H, et al.: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001."},{"issue":"Suppl2","key":"62_CR2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/annonc\/5.suppl_2.S91","volume":"5","author":"R.I. Fisher","year":"1994","unstructured":"Fisher RI, Gaynor ER, Dahlberg S, et al.: A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate-or high-grade non-Hodgkin\u2019s lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann Oncol 1994, 5(Suppl 2):91\u201395.","journal-title":"Ann Oncol"},{"key":"62_CR3","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","volume":"103","author":"A. Gallamini","year":"2004","unstructured":"Gallamini A, Stelitano C, Calvi R, et al.: Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004, 103:2474\u20132479.","journal-title":"Blood"},{"key":"62_CR4","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","volume":"15","author":"K.J. Savage","year":"2004","unstructured":"Savage KJ, Chhanabhai M, Gascoyne RD, et al.: Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004, 15:1467\u20131475.","journal-title":"Ann Oncol"},{"key":"62_CR5","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1023\/A:1008418727472","volume":"9","author":"A. Lopez-Guillermo","year":"1998","unstructured":"Lopez-Guillermo A, Cid J, Salar A, et al.: Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol 1998, 9:849\u2013855.","journal-title":"Ann Oncol"},{"key":"62_CR6","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2141.2001.02743.x","volume":"113","author":"S. Sallah","year":"2001","unstructured":"Sallah S, Wan JY, Nguyen NP: Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol 2001, 113:185\u2013187.","journal-title":"Br J Haematol"},{"key":"62_CR7","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/annonc\/mdf033","volume":"13","author":"T. Rudiger","year":"2002","unstructured":"Rudiger T, Weisenburger DD, Anderson JR, et al.: Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin\u2019s Lymphoma Classification Project. Ann Oncol 2002, 13:140\u2013149.","journal-title":"Ann Oncol"},{"key":"62_CR8","first-page":"76","volume":"92","author":"C. Gisselbrecht","year":"1998","unstructured":"Gisselbrecht C, Gaulard P, Lepage E, et al.: Prognostic significance of T-cell phenotype in aggressive non-Hodgkin\u2019s lymphomas. Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte (GELA). Blood 1998, 92:76\u201382.","journal-title":"Blood"},{"key":"62_CR9","doi-asserted-by":"crossref","first-page":"811a","DOI":"10.1182\/blood.V106.11.811.811","volume":"106","author":"J.M. Vose","year":"2005","unstructured":"Vose JM: The International PTCL Project. International Peripheral T-Cell Lymphoma (PTCL) Clinical and Pathologic Review Project: poor outcome by prognostic indices and lack of efficacy with anthracyclines [abstract]. Blood 2005, 106:811a.","journal-title":"Blood"},{"key":"62_CR10","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1093\/annonc\/mdh409","volume":"15","author":"J.O. Armitage","year":"2004","unstructured":"Armitage JO, Vose JM, Weisenburger DD: Towards understanding the peripheral T-cell lymphomas. Ann Oncol 2004, 15:1447\u20131449.","journal-title":"Ann Oncol"},{"key":"62_CR11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.blre.2007.03.001","volume":"21","author":"K.J. Savage","year":"2007","unstructured":"Savage KJ: Peripheral T-cell lymphomas. Blood Rev 2007, 21:201\u2013216.","journal-title":"Blood Rev"},{"key":"62_CR12","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","volume":"22","author":"P. Corradini","year":"2004","unstructured":"Corradini P, Dodero A, Zallio F, et al.: Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin\u2019s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004, 22:2172\u20132176.","journal-title":"J Clin Oncol"},{"key":"62_CR13","first-page":"S10-11","volume":"24","author":"L. Gianni","year":"1997","unstructured":"Gianni L: Anthracycline resistance: the problem and its current definition. Semin Oncol 1997, 24:S10-11\u2013S10-17.","journal-title":"Semin Oncol"},{"key":"62_CR14","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1023\/A:1008409601731","volume":"9","author":"P.L. Zinzani","year":"1998","unstructured":"Zinzani PL, Magagnoli M, Bendandi M, et al.: Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol 1998, 9:1351\u20131353.","journal-title":"Ann Oncol"},{"key":"62_CR15","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1124\/mol.63.4.862","volume":"63","author":"M.A. Moufarij","year":"2003","unstructured":"Moufarij MA, Phillips DR, Cullinane C: Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines. Mol Pharmacol 2003, 63:862\u2013869.","journal-title":"Mol Pharmacol"},{"key":"62_CR16","first-page":"72","volume":"22","author":"G.J. Peters","year":"1995","unstructured":"Peters GJ, Bergman AM, Ruiz van Haperen VW, et al.: Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995, 22:72\u201379.","journal-title":"Semin Oncol"},{"key":"62_CR17","first-page":"521","volume":"2","author":"A.M. Bergman","year":"1996","unstructured":"Bergman AM, Ruiz van Haperen VW, Veerman G, et al.: Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996, 2:521\u2013530.","journal-title":"Clin Cancer Res"},{"key":"62_CR18","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/annonc\/mdg496","volume":"14","author":"T. Baetz","year":"2003","unstructured":"Baetz T, Belch A, Couban S, et al.: Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin\u2019s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 2003, 14:1762\u20131767.","journal-title":"Ann Oncol"},{"key":"62_CR19","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1445-5994.2007.01397.x","volume":"37","author":"A. Spencer","year":"2007","unstructured":"Spencer A, Reed K, Arthur C: Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim. Intern Med J 2007, 37:760\u2013766.","journal-title":"Intern Med J"},{"key":"62_CR20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3816\/CLM.2004.n.009","volume":"5","author":"C. Emmanouilides","year":"2004","unstructured":"Emmanouilides C, Colovos C, Pinter-Brown L, et al.: Pilot study of fixed-infusion rate gemcitabine with cisplatin and dexamethasone in patients with relapsed or refractory lymphoma. Clin Lymphoma 2004, 5:45\u201349.","journal-title":"Clin Lymphoma"},{"key":"62_CR21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3324\/haematol.10737","volume":"92","author":"H.T. Arkenau","year":"2007","unstructured":"Arkenau HT, Chong G, Cunningham D, et al.: Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica 2007, 92:271\u2013272.","journal-title":"Haematologica"},{"key":"62_CR22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00280-005-0136-y","volume":"58","author":"J.G. Kim","year":"2006","unstructured":"Kim JG, Sohn SK, Chae YS, et al.: CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemother Pharmacol 2006, 58:35\u201339.","journal-title":"Cancer Chemother Pharmacol"},{"key":"62_CR23","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/1042819031000077124","volume":"44","author":"E.S. Wang","year":"2003","unstructured":"Wang ES, O\u2019Connor O, She Y, et al.: Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma 2003, 44:1027\u20131035.","journal-title":"Leuk Lymphoma"},{"key":"62_CR24","first-page":"551","volume":"69","author":"F.A. Schmid","year":"1985","unstructured":"Schmid FA, Sirotnak FM, Otter GM, et al.: New folate analogs of the 10-deaza-aminopterin series: markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice. Cancer Treat Rep 1985, 69:551\u2013553.","journal-title":"Cancer Treat Rep"},{"key":"62_CR25","first-page":"26","volume":"12","author":"F.M. Sirotnak","year":"1984","unstructured":"Sirotnak FM, DeGraw JI, Schmid FA, et al.: New folate analogs of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models. Cancer Chemother Pharmacol 1984, 12:26\u201330.","journal-title":"Cancer Chemother Pharmacol"},{"key":"62_CR26","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/01.cco.0000245309.74767.20","volume":"18","author":"O.A. O\u2019Connor","year":"2006","unstructured":"O\u2019Connor OA: Pralatrexate: an emerging new agent with activity in T-cell lymphomas. Curr Opin Oncol 2006, 18:591\u2013597.","journal-title":"Curr Opin Oncol"},{"key":"62_CR27","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1365-2141.2007.06658.x","volume":"139","author":"O.A. O\u2019Connor","year":"2007","unstructured":"O\u2019Connor OA, Hamlin PA, Portlock C, et al.: Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol 2007, 139:425\u2013428.","journal-title":"Br J Haematol"},{"key":"62_CR28","doi-asserted-by":"crossref","first-page":"400a","DOI":"10.1182\/blood-2005-12-4938","volume":"108","author":"O.A. O\u2019Connor","year":"2006","unstructured":"O\u2019Connor OA, Hamlin PA, Gerecitano J, et al.: Pralatrexate (PDX) produces durable complete remissions in patients with chemotherapy resistant precursor and peripheral T-cell lymphomas: results of the MSKCC phase I\/II experience [abstract]. Blood 2006, 108:400a.","journal-title":"Blood"},{"key":"62_CR29","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/1078-0432.CCR-05-0331","volume":"12","author":"L.E. Toner","year":"2006","unstructured":"Toner LE, Vrhovac R, Smith EA, et al.: The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin\u2019s lymphoma. Clin Cancer Res 2006, 12:924\u2013932.","journal-title":"Clin Cancer Res"},{"key":"62_CR30","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","volume":"103","author":"G. Enblad","year":"2003","unstructured":"Enblad G, Hagberg H, Erlanson M, et al.: A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2003, 103:2920\u20132924.","journal-title":"Blood"},{"key":"62_CR31","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1158\/1078-0432.CCR-06-1275","volume":"12","author":"S.J. Rodig","year":"2006","unstructured":"Rodig SJ, Abramson JS, Pinkus GS, et al.: Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 2006, 12:7174\u20137179.","journal-title":"Clin Cancer Res"},{"key":"62_CR32","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3324\/haematol.10767","volume":"92","author":"P.P. Piccaluga","year":"2007","unstructured":"Piccaluga PP, Agostinelli C, Righi S, et al.: Expression of CD52 in peripheral T-cell lymphoma. Haematologica 2007, 92:566\u2013567.","journal-title":"Haematologica"},{"key":"62_CR33","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","volume":"24","author":"P. Went","year":"2006","unstructured":"Went P, Agostinelli C, Gallamini A, et al.: Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol 2006, 24:2472\u20132479.","journal-title":"J Clin Oncol"},{"key":"62_CR34","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00280-007-0469-9","volume":"60","author":"J.G. Kim","year":"2007","unstructured":"Kim JG, Sohn SK, Chae YS, et al.: Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol 2007, 60:129\u2013134.","journal-title":"Cancer Chemother Pharmacol"},{"key":"62_CR35","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","volume":"110","author":"A. Gallamini","year":"2007","unstructured":"Gallamini A, Zaja F, Patti C, et al.: Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007, 110:2316\u20132323.","journal-title":"Blood"},{"key":"62_CR36","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1200\/JCO.2006.07.8972","volume":"25","author":"S.M. Ansell","year":"2007","unstructured":"Ansell SM, Horwitz SM, Engert A, et al.: Phase I\/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin\u2019s lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007, 25:2764\u20132769.","journal-title":"J Clin Oncol"},{"key":"62_CR37","doi-asserted-by":"crossref","first-page":"2637a","DOI":"10.1182\/blood.V104.11.2637.2637","volume":"104","author":"A. Forero-Torres","year":"2004","unstructured":"Forero-Torres A, Bernstein S, Gopal A, et al.: SGN-30 (anti-CD30 monoclonal antibody) is active and well tolerated in patients with refractory or recurrent systemic anaplastic large cell lymphoma [abstract]. Blood 2004, 104:2637a.","journal-title":"Blood"},{"key":"62_CR38","doi-asserted-by":"crossref","first-page":"3409a","DOI":"10.1182\/blood.V110.11.3409.3409","volume":"110","author":"F. D\u2019Amore","year":"2007","unstructured":"D\u2019Amore F, Radford J, Jerkeman M, et al.: Zanolimumab (HuMax-CD4TM), a fully human monoclonal antibody: efficacy and safety in patients with relapsed or treatment-refractory non-cutaneous CD4+ T-cell lymphoma [abstract]. Blood 2007, 110:3409a.","journal-title":"Blood"},{"key":"62_CR39","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3816\/CLM.2000.n.009","volume":"1","author":"F.M. Foss","year":"2000","unstructured":"Foss FM: DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma. Clin Lymphoma 2000, 1:110\u2013116; discussion 117.","journal-title":"Clin Lymphoma"},{"key":"62_CR40","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2141.2006.06457.x","volume":"136","author":"N.H. Dang","year":"2007","unstructured":"Dang NH, Pro B, Hagemeister FB, et al.: Phase II trial of denileukin diftitox for relapsed\/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 2007, 136:439\u2013447.","journal-title":"Br J Haematol"},{"key":"62_CR41","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/bjo.2006.091165","volume":"90","author":"J.B. Ruddle","year":"2006","unstructured":"Ruddle JB, Harper CA, Honemann D, et al.: A denileukin diftitox (Ontak) associated retinopathy? Br J Ophthalmol 2006, 90:1070\u20131071.","journal-title":"Br J Ophthalmol"},{"key":"62_CR42","doi-asserted-by":"crossref","first-page":"2461a","DOI":"10.1182\/blood.V108.11.2461.2461","volume":"108","author":"F.M. Foss","year":"2006","unstructured":"Foss FM, Sjak-Shie N, Goy A, et al.: A Phase II study of denileukin diftitox (Ontak) with CHOP chemotherapy in patients with newly-diagnosed aggressive T-cell lymphomas, the CONCEPT trial: interim analysis [abstract]. Blood 2006, 108:2461a.","journal-title":"Blood"},{"key":"62_CR43","doi-asserted-by":"crossref","first-page":"315","DOI":"10.7164\/antibiotics.47.315","volume":"47","author":"H. Ueda","year":"1994","unstructured":"Ueda H, Manda T, Matsumoto S, et al.: FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J Antibiot (Tokyo) 1994, 47:315\u2013323.","journal-title":"J Antibiot (Tokyo)"},{"key":"62_CR44","doi-asserted-by":"crossref","first-page":"301","DOI":"10.7164\/antibiotics.47.301","volume":"47","author":"H. Ueda","year":"1994","unstructured":"Ueda H, Nakajima H, Hori Y, et al.: FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo) 1994, 47:301\u2013310.","journal-title":"J Antibiot (Tokyo)"},{"key":"62_CR45","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1271\/bbb.58.1579","volume":"58","author":"H. Ueda","year":"1994","unstructured":"Ueda H, Nakajima H, Hori Y, et al.: Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells. Biosci Biotechnol Biochem 1994, 58:1579\u20131583.","journal-title":"Biosci Biotechnol Biochem"},{"key":"62_CR46","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0026-895X(25)09793-7","volume":"46","author":"J.S. Lee","year":"1994","unstructured":"Lee JS, Paull K, Alvarez M, et al.: Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol 1994, 46:627\u2013638.","journal-title":"Mol Pharmacol"},{"key":"62_CR47","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood.V98.9.2865","volume":"98","author":"R.L. Piekarz","year":"2001","unstructured":"Piekarz RL, Robey R, Sandor V, et al.: Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001, 98:2865\u20132868.","journal-title":"Blood"},{"key":"62_CR48","doi-asserted-by":"crossref","first-page":"8027","DOI":"10.1200\/jco.2007.25.18_suppl.8027","volume":"25","author":"R. Piekarz","year":"2007","unstructured":"Piekarz R, Frye R, Wright J, et al.: Update of the NCI multi-institutional phase II trial of romidepsin, FK228, for patients with cutaneous or peripheral T-cell lymphoma [ASCO abstract]. J Clin Oncol 2007, 25:8027.","journal-title":"J Clin Oncol"},{"key":"62_CR49","first-page":"718","volume":"8","author":"V. Sandor","year":"2002","unstructured":"Sandor V, Bakke S, Robey RW, et al.: Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002, 8:718\u2013728.","journal-title":"Clin Cancer Res"},{"key":"62_CR50","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1158\/1078-0432.CCR-05-2095","volume":"12","author":"R.L. Piekarz","year":"2006","unstructured":"Piekarz RL, Frye AR, Wright JJ, et al.: Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 2006, 12:3762\u20133773.","journal-title":"Clin Cancer Res"},{"key":"62_CR51","doi-asserted-by":"crossref","first-page":"2579a","DOI":"10.1182\/blood.V110.11.2579.2579","volume":"110","author":"T. Reiman","year":"2007","unstructured":"Reiman T, Finch D, Chua N, et al.: First report of a phase II clinical trial of lenalidomide oral therapy for peripheral T-cell lymphoma [abstract]. Blood 2007, 110:2579a.","journal-title":"Blood"},{"key":"62_CR52","first-page":"702","volume":"90","author":"P.L. Zinzani","year":"2005","unstructured":"Zinzani PL, Alinari L, Tani M, et al.: Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica 2005, 90:702\u2013703.","journal-title":"Haematologica"},{"key":"62_CR53","doi-asserted-by":"crossref","first-page":"8069a","DOI":"10.1200\/jco.2007.25.18_suppl.8069","volume":"25","author":"J. Moon","year":"2007","unstructured":"Moon J, Kim J, Sohn S, et al.: Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas [ASCO abstract]. J Clin Oncol 2007, 25:8069a.","journal-title":"J Clin Oncol"},{"key":"62_CR54","doi-asserted-by":"crossref","first-page":"2640a","DOI":"10.1182\/blood.V104.11.2640.2640","volume":"104","author":"E. Weidmann","year":"2004","unstructured":"Weidmann E, Hess G, Krause SW, et al.: Combination chemoimmunotherapy using alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) is an effective first-line regimen in peripheral T-cell lymphomas [abstract]. Blood 2004, 104:2640a.","journal-title":"Blood"},{"issue":"18S","key":"62_CR55","doi-asserted-by":"crossref","first-page":"7538","DOI":"10.1200\/jco.2006.24.18_suppl.7538","volume":"24","author":"L.H. Trumper","year":"2006","unstructured":"Trumper LH, Hohloch K, Kloess M, et al.: CHOP\/CHOEP-14 followed by consolidation with alemtuzumab in untreated aggressive T-cell lymphomas (DSHNHL 2003-1): feasibility and toxicity of a phase II trial of the German High Grade Non-Hodgkin\u2019s Lymphoma Group DSHNHL [ASCO abstract]. J Clin Oncol 2006, 24(18S):7538.","journal-title":"J Clin Oncol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-008-0062-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-008-0062-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-008-0062-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T19:27:48Z","timestamp":1738438068000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-008-0062-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["62"],"URL":"https:\/\/doi.org\/10.1007\/s11912-008-0062-3","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"type":"print","value":"1523-3790"},{"type":"electronic","value":"1534-6269"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}